The β-galactosidase (BgaC) of the zoonotic pathogen Streptococcus suis is a surface protein without the involvement of bacterial virulence

Dan Hu, Fengyu Zhang, Huimin Zhang, Lina Hao, Xiufang Gong, Meiling Geng, Min Cao, Feng Zheng, Jin Zhu, Xiuzhen Pan, Jiaqi Tang, Youjun Feng & Changjun Wang

1Department of Epidemiology, Research Institute for Medicine of Nanjing Command, Nanjing 210002, P. R. China, 2Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P. R. China, 3Department of Medical Microbiology and Parasitology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, P. R. China, 4University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.

Streptococcal pathogens have evolved to express exoglycosidases, one of which is BgaC β-galactosidase, to deb glycosidate host surface glycolconjugates with exposure of the polysaccharide receptor for bacterial adherence. The paradigm BgaC protein is the bgaC product of Streptococcus, a bacterial surface-exposed β-galactosidase. Here we report the functional definition of the BgaC homologue from an epidemic Chinese strain 05ZYH33 of the zoonotic pathogen Streptococcus suis. Bioinformatics analyses revealed that S. suis BgaC shared the conserved active sites (W240, W243 and Y454). The recombinant BgaC protein of S. suis was purified to homogeneity. Enzymatic assays confirmed its activity of β-galactosidase. Also, the hydrolysis activity was found to be region-specific and sugar-specific for the Gal β-1,3-GlcNAc moiety of oligosaccharides. Flow cytometry analyses combined with immune electron microscopy demonstrated that S. suis BgaC is an atypical surface-anchored protein in that it lacks the “LPXTG” motif for typical surface proteins. Integrative evidence from cell lines and mice-based experiments showed that an inactivation of bgaC does not significantly impair the ability of neither adherence nor anti-phagocytosis, and consequently failed to attenuate bacterial virulence, which is somewhat similar to the scenario seen with S. pneumoniae. Therefore we concluded that S. suis BgaC is an atypical surface-exposed protein without the involvement of bacterial virulence.

Streptococcus suis serotype 2 (S. suis, SS2) is recognized as a serious swine pathogen that also frequently leads to the opportunistic human infections clinically featuring with meningitis, septicemia, arthritis, etc. S. suis infections have been recorded in over 30 countries and/or regions, and claimed for no less than 850 human cases worldwide, some of which are lethal infections. Of particular note, two big-scale endemics of human SS2 infections had ever occurred in China in 1998 and 2005, and a new disease form, streptococcal toxic shock-like syndrome (STSS) appeared in the SS2-infected patients. Unfortunately, the molecular mechanism underlying STSS remains fragmentary or limited. Sporadic cases of human SS2 infections were also recorded in China. In addition to the known virulence factors like capsule polysaccharide (CPS), suilysin, muraminidase released-protein (MRP), etc., a collection of new virulence determinants have been elucidated that are grouped as follows: 1) transcription factors (such as catabolite control protein A CcpA, Rgg regulator, zinc uptake regulator (Zur) and ferric uptake regulator (Fur)); 2) the two component system (such as salk-salR, virR-virS, cia-ciaH and ikh-ikh); 3) enzymes involved in central metabolisms (e.g., Glutamine synthetase, GluDH, N-acetylglucosamine deacetylase (PgdA), sialic acid synthesis-associated enzymes NeuB & NeuC and Inosine 5-monophosphate dehydrogenase (ImpdH)); 4) quorum sensing system (LuxS, IroU, Pzov, Pzox, Polysaccharide exoenzyme, etc.). It seemed likely that we have in part delineated the pathogenesis of S. suis infections. Efficient adherence to host cells is critical for Streptococcal successful infections. In general, a collection of bacterial secreted and/or surface-anchored enzymes have been suggested to participate into this process. In the
case of *S. pneumoniae*, at least three types of exoglycosidases that included NanA (neuraminidase)
\(^{39}\), BgaA & BgaC (\(\beta\)-galactosidase)\(^{38,40}\) and StrH (N-acetylglucosaminidase)\(^{39}\) are sequentially involved in the deglycosidation of host surface glycoconjugates for exposure of its preferred host oligosaccharide receptor\(^{39,40}\). Similar to the scenario observed with *S. pneumoniae*, the closely relative *S. suis* is also supposed to encounter a variety of glycoconjugates on the infected host cell surface (e.g., Mucin)\(^{38,41}\), and might evolve the similar strategy. However this hypothesis required further experimental validation.

\(\beta\)-galactosidase widespread in almost three domains of life, are a group of enzymes (EC3.2.1.23) with ability to catalyze the hydrolysis/release of the terminal non-reducing galactose from the oligosaccharides. The paradigm version of this family is *E. coli* lacZ product, which is a large/soluble polypeptide of 1024 amino acids/residues (~120 kDa) (http://www.ecogene.org/old/geneinfo.php).
Figure 2 | Purification, identification and enzymatic characterization of the recombinant BgaC protein. (A). 12% SDS-PAGE profile of the purified BgaC protein of S. suis. The expected protein is indicated with an arrow. “M” is the abbreviation for protein molecular weight. The numbers on left hand represent protein size (kDa). (B). Western blotting analyses for the recombinant BgaC protein. (C). Enzymatic parameters determined for the BgaC β-galactosidase. The protocol used to measure the activity of β-galactosidase is found in section of Materials and Methods. Designations: Km, Michaelis constant; Vm, The maximum rate; Kcat: a rate constant. (D). MS-based identification of the recombinant BgaC protein. The tryptic peptides identified to match the BgaC sequence are given in underlined type.

Figure 3 | HPLC analyses for hydrolysis products of polysaccharides by S. suis BgaC enzyme. (A). HPLC profile of PA-labeled sugar chain 028 with or without treatment of the recombinant S. suis BgaC protein. (B). HPLC test of PA-labeled sugar chain 042 following the S. suis BgaC protein-mediated hydrolysis. (C). HPLC assay for PA-labeled sugar chain 044 after the hydrolysis by the S. suis BgaC β-galactosidase. Minus: without addition of the BgaC protein; plus: addition of the BgaC protein. Designations: a.u., arbitrary units.
eg_id=EG10527) and required for lactose utilization. By contrast, *S. pneumoniae* BgaA is a typical surface-displayed β-galactosidase in that it is featuring "LPXTG" surface-anchoring motif. However, the other β-galactosidase BgaC of this organism might be atypical surface-associated protein without any known surface indicators/s signals. Very recently, structural study of BgaC pointed out its solution structure of a dimer and dissected its catalytic mechanism. As anticipated, the genomic analyses of *S. suis* 05ZYH33 strain discovered a *bgaC* homologue (SSU0449) (Fig. 1). Given its unique biological properties and important relevance of BgaC protein in the counterpart microorganism *S. pneumoniae*, we thereby employed integrative approaches (ranging from bioinformatics, biochemistry, bacterial genetics, infection/immunology to bacterial pathogenesis) to systemically investigate the *S. suis* BgaC protein.

**Results**

**Discovery of a BgaC homologue from *S. suis***. The annotation for functional genome of *S. suis* 05ZYH33, an epidemic Chinese strain, assigned the 05SSU0449 locus as the putative *bgaC* whose protein product belongs to the β-galactosidase sub-clade of the glycosyl hydrolase family 35. Multiple sequence alignments of 05SSU0449-encoding product with the prototypical BgaC encoded by *S. pneumoniae* revealed 1) the overall similarity is 63%; 2) the N-terminus of BgaC protein is pretty conserved, whereas the
C-terminus differs quite bit; 3) they shared the three identical residues for catalytic activity (240W, 243W & 454Y) (Fig. 1A). Of particular note, the modeled tertiary structure of *S. suis* BgaC (Fig. 1C) is almost identical to that of the paradigm member from *S. pneumoniae* (Fig. 1B) in that the perfect matched architectures are visualized through structural superposition (Fig. 1D). Also, *S. suis* bgaC has a pool of active transcripts revealed by our RT-PCR experiments (not shown). We therefore speculated that *S. suis* bgaC is a functional homologue (Fig. 1). This required further experimental validation.

**S. suis BgaC has the activity of β-galactosidase.** To gain preliminary glimpse of enzymatic/biochemical aspects, we prepared the recombinant form of the *S. suis* BgaC protein. The N-terminal 6XHis tagged BgaC was overexpressed in *E. coli* system and purified through nickel column-based affinity chromatography, and the purity was further judged by 12% SDS-PAGE (Fig. 2A). As expected, the molecular weight of the acquired protein is about 63 kDa (Fig. 2A), which is in much consistency with the scenario seen with Western blot using anti-BgaC mouse sera. Of note, Maldi-Toff spectrometry-based determination proved the identity of the recombinant BgaC protein we obtained (Fig. 2D).

Subsequently, the recombinant BgaC protein was subjected to β-galactosidase assays with pNPG as the substrates. We found that the optimal temperature, optimal reaction time and optimal pH of this enzyme is 42°C, 30 min, and 5.5, respectively (not shown). Additionally, the optimal concentration for the substrate pNPG is 10 mM (not shown). On the basis of the above enzymatic reaction conditions we optimized, the *S. suis* BgaC was proved to obviously possess the activity of β-galactosidase with Km of 0.398 mM, Kcat of $5.63 \times 10^2/s$ and Vm$7.43 \times 10^2 \text{mM/min}$ (Fig. 2C). It seemed likely that our structure-guided prediction in this case is correct (Fig. 1).

**Linkage specificity of S. suis BgaC hydrolysis activity.** To further elucidate the linkage specificity of *S. suis* BgaC-mediated hydrolysis activity, we compared three kinds of amino pyridine (PA)-tagged sugar chains as substrates used in our set-up hydrolysis reactions as Jeong *et al.* reported with little change. These sugar chains included 028 (asialo GM1-tetrasaccharide), 042 (lacto-N-tetraose) and 044 (lacto-N-fucopentaose II) (Table 2). Subsequently, HPLC was adopted to determine whether *S. suis* BgaC was able to liberate galactose moiety from the above tested substrates tested. Obviously, BgaC treatment failed to give any position-shift for the peaks of HPLC chromatogram of either PA-labeled sugar chain 028 (Fig. 3A) or PA-labeled sugar chain 044 (Fig. 3C). By contrast, elution time of the specific peak is changed for the PA-labeled sugar chain 042 upon the BgaC treatment; (Fig. 3B). It suggested that *S. suis* BgaC specifically cleaves Galβ1-3GlcNAc group containing sugar chain 042, while not hydrolyze group containing

![Figure 5](https://example.com/fig5.png) Immune electron microscopy-based analyses of the BgaC protein. The BgaC protein is visualized to display on bacterial cell surface of *S. suis* 2 using the post-immunization sera (Panel B), whereas not using the pre-immunization sera (Panel A).

![Figure 6](https://example.com/fig6.png) No apparent role of *S. suis* BgaC in bacterial pathogenesis. (A). Comparison of bacterial adherence capability of the ΔbgaC mutant with the wild type strain 05ZYH33. Hep-2 cells were applied here. Data shown here are means ± SD of intracellular bacteria/ml. (B). Evaluation of anti-phagocytosis ability of *S. suis* strains by fresh macrophages RAW264.7. (C). anti-phagocytosis of *S. suis* strains by RAW264.7 macrophages. Intracellular bacteria were recovered from cell lysates in 1 h post-infection. The results are expressed as means ± SD of recovered bacteria/ml. (D). Evaluation of role of *S. suis* BgaC in bacterial virulence using mice infection model. Statistical analyses were performed by using a Student t test. No statistically significant differences were considered.
Table 1 | Bacterial strains, plasmid, and cell lines used in this study

| Strains, plasmids or cell lines | Characteristicsa | Refs or Origin |
|--------------------------------|------------------|----------------|
| E. coli strains               |                  |                |
| DH5α                          | The cloning host | Promega        |
| BL21                          | The expression host | Promega      |
| S. suis 2                     |                  |                |
| 05ZYH33                       |                  |                |
| ΔbgaC                         |                  |                |
| Plasmids                      |                  |                |
| pSET2                         |                  |                |
| pET28a                        |                  |                |
| pMD18-T                       |                  |                |
| pUC18                         |                  |                |
| Cell lines                    |                  |                |
| Raw 264.7                     |                  |                |
| Hep-2                         |                  |                |
|                               |                  |                |
| *Spc*, spectinomycin resistance; Amp*, ampicillin resistance; Kan*, kanamycin resistance. |

Gal β1–3 GalNAc sugar chain 028 and Gal β1–3 GlcNAc terminally modified sugar chain 044 (Table 2).

S. suis BgaC is a surface-exposed protein. Two different approaches (one is the fluorescence-activated cell sorting (FACS) analysis, the other is immune electron microscopy) were applied to assess the subcellular location of BgaC on S. suis (Fig. 4 & 5). FACS analyses suggested that the unlabeled SS2 is distributed normally (Fig. 4A) with a mean fluorescence intensity (MFI) close to that of the labeled SS2 treated with mouse pre-immunization serum (Fig. 4B and 4C). However, the result in flow diagram is clear that the peaks shifted to the right upon treatment with the mouse anti-BgaC post-immunization serum (Fig. 4D). In fact, the MFI of bacteria treated with the mouse anti-BgaC post-immune serum was about 3-fold higher than the pre-immune mouse serum treated with a negative control group (Fig. 4E). In contrast to the negative control in which the pre-immunization sera were involved (Fig. 5A), immune-gold assays elucidated that BgaC protein particles are visualized on bacterial cell surface of S. suis with treatment of the post-immunization sera (Fig. 5B). Given that the above combined results are similar to our earlier observation with the surface-localized enolase25, we concluded that S. suis BgaC does act as a surface-anchored protein with the activity of β-galactosidase.

S. suis BgaC plays no detectable roles in bacterial pathogenesis. To probe possible roles of the bgaC gene in S. suis infection, we constructed the ΔbgaC mutant and compared its phenotype with that of the wild type strain 05ZYH33 (Fig. 6). The cell tests conducted here were based on both Hep-2 cell line (Fig. 6A) and RAW264.7 macrophage (Fig. 6C). No significant effect on bacterial adherence to Hep-2 cell line was observed between the ΔbgaC mutant and its parental strain 05ZYH33 (Fig. 6A). Similarly, the disruption of bgaC gene failed to exert obvious effects on the ability of bacterial anti-phagocytosis (Fig. 6B and C).

Mice infection assays were further adopted to address the function of the bgaC gene to bacterial virulence (Fig. 6D). All the mice infected with the wild type strain 05ZYH33 were sick within 24 hours, most of which died (Fig. 6D). By contrast, mice of the negative control group inoculated with THB all survived (Fig. 6D). Most of mice infected with the ΔbgaC mutant died within two days. It seemed likely that no significant difference between WT and the ΔbgaC mutant in S. suis pathogenicity, which is consistent with scenarios observed in cell lines-based experiments (Fig. 6A–C). Thus we believed that S. suis BgaC has no roles in bacterial virulence, which is in agreement with that of S. pneumoniae38.

Discussion
To the best of our knowledge, our findings might represent/provide the integrative evidence that the zoonotic pathogen S. suis is a second paradigm organism in which the bgaC gene encoded an atypical surface-exported protein with the essence of β-galactosidase38. Unlike another surface-displayed exoglycosidase BgaA39,40, it seemed likely that the BgaC exoglycosidase of both S. pneumoniae38 and S. suis (Fig. 5) does not significantly contribute to bacterial virulence. It remains possible that BgaC might augment the critical roles of other known three relevant surface exoglycosidases (NanA, BgaA & StrH) in Streptococcal infections39,40, but required extensive evidence. We also noted that the bgaC gene is widespread in almost 35 serotypes of S. suis pathogens (not shown), suggesting that it is a conserved exoglycosidase-encoding gene. The presence of BgaC-type β-galactosidase in Streptococcus species might be anticipated to reflect the consequence for long-term of Streptococcus with its host niche. The reason lied in that the physiological advantage that bacteria acquired is exploiting BgaC-mediated deglycosylation of host cell surface glycolconjugates to partially facilitate exposing the polysaccharide receptor for efficient bacterial adherence39,40.

Given the fact that both the flow cytometry-based assay and the immune electron microscopy-aided visualization illustrated that S. suis BgaC is localized on bacterial surface (Fig. 4 and 5), although it lacks the typical “LPXTG” motif for classic surface proteins (Fig. 1), we thereby believed that S. suis BgaC acts as an atypical surface protein. In particular, the integrative evidence from cell lines and

Table 2 | Hydrolysis of terminal galactose of various sugar chains by BgaC

| Sugar chain                        | Structure                             | Hydrolysis* |
|-----------------------------------|---------------------------------------|-------------|
| Lacto-N-tetraose (PA-sugar chain 042) | Gal β1–3 GlcNAc β1–3 Gal β1–4 Glc-PA | +           |
| Asialo GM1-tetrasaccharide (PA-sugar chain 028) | Gal β1–3 GalNAc β1–4 Gal β1–4 Glc-PA | –           |
| Lacto-N-fucopentaose II (PA-sugar chain 044) | Gal β1–3 GlcNAc β1–3 Gal β1–4 Fuc-PA | –           |

*50 pmol of each substrate was incubated with 1.6 mU BgaC or in a 50 μl reaction mixture (1× PBS, 10 mM MgCl2, 10 mM DTT) for 20 h at 30°C. Release of the terminal galactose from substrates was analyzed by HPLC. The sugar chains 028, 042 and 044 were purchased from Takara (Japan).
mice-based experiments clearly showed that the disruption of bgaC does not significantly exert any effect on the abilities of bacterial adherence and anti-phagocytosis, and consequently failed to attenuate bacterial virulence, which is somewhat similar to the scenario seen with S. pneumoniae.

Interestingly, HPLC-based analyses for hydrolysis products of oligosaccharides revealed clearly that S. suis BgaC exhibits the region-specific and sugar-specific hydrolysis activity for the Gal β-1, 3-GlcNAc moiety of oligosaccharides (Table 2 and Fig. 3). This observation is much consistent with scenario seen with the parasite BgaC of S. pneumoniae84. Apparently, it suggested the functional conservation/selection of BgaC protein from different microorganisms, and might point out its limited capability (not promiscous) to deglycosylate host surface glycolconjugates, which is probably due to selection pressure during the process of host-pathogen co-evolution/interaction.

The future research directions regarding to the BgaC protein lied in the following three aspects: 1) given the fact that pneumococcal and S. suis BgaC protein are surface-displayed, we expect to analyze our data to other Streptococcus species (e.g., S. dysgalactiae, Fig. 1A), which might delineate a common scenario for cell biology of BgaC protein; 2) we are planning to examine if it is a good antigen with potential to develop into a diagnostic antigen for laboratory/field detection for S. suis infection. We had ever obtained the similar success in the cases of SAO protein85 and enolase enzyme86; 3) to further our understanding of the catalysis mechanism/substrate specificity of BgaC, we are quite interested in resolving the crystal structures of BgaC alone and/or its complex with substrate by employing X-ray crystallography87.

In summary, BgaC protein as a new member is assigned to a family/list of surface proteins from the zoonotic pathogen S. suis. Similar to the scenario seen with its counterpart of S. pneumoniae, it is not obviously involved in bacterial virulence.

### Methods

**Bacterial strains, cells and growth conditions.** The bacterial strains, plasmids and cell lines used here are listed in Table 1. The S. suis 2 strains were maintained on both Todd–Hewitt broth (THB; Difco Laboratories, Detroit, MI) agar and THB liquid media at 37 °C. When required, 5% (vol/vol) sheep blood is supplemented. Escherichia coli DH5α and BL21 (DE3) separately served as the gene cloning host and the protein expression host, which were routinely kept in Luria-Bertani (LB) broth agar and/or liquid media or plated on LB agar at 37 °C overnight. All the antibiotics were purchased from Sigma and were used as follows: Spectinomycin, 100 μg/ml for S. suis; Ampicillin, 100 μg/ml for E. coli and Kanamycin, 50 μg/ml for E. coli.

Two types of cell lines used here separately included the human laryngeal epithelial cell Hep-2 (CCCTC GCCD004) and the mouse macrophage Raw 264.7 (ATCC TIB-71, Rockville, MD, USA) (Table 1). As we described earlier25 with minor changes, FCM was conducted to examine the sub-cellular localization of BgaC on S. suis cells. Briefly, the overnight cultures of S. suis 05ZYH33 were harvested by the centrifugation at 8000 g. Then the bacteria were washed with 0.01 M PBS (pH 7.4), adjusted to 10^8 CFU/ml, and incubated with mouse anti-BgaC sera or pre-immune sera for 1 h at 4 °C. Finally, bacterial cells were fixed in 4% paraformaldehyde for 30 min and examined using a flow cytometer, following the 1 h of incubation with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Sigma).

**Immune electron microscopy.** Overnight culture of S. suis 05ZYH33 grown in THB media (~5 ml) was pelleted by spinning and re-suspended in 500 μl of PBS (pH 8.0). 20 μl of the bacterial suspension was placed on nickel-Formvar grids (EMCN, Beijing, China) and partially air-dried. The bacteria were fixed with 2.5% glutaraldehyde for 10 min. After being blocked for 30 min with 10% normal donkey serum in dilution buffer (PBS containing 1% BSA (bovine serum albumin) plus 1% Tween 20, pH 8.0), the grids were soaked in 50 ul of mouse anti-BgaC sera (or pre-immunization sera, in 25% dilution) for 1 h at room temperature (RT). After three rounds of washes with PBS-1% Tween 20, the grids were transferred to 50 μl of 15 moll gold-conjugated goat anti-mouse IgG (Beijing Biosynthesis Biotechnology Co. Ltd) diluted 1:30 in dilution buffer, and incubated at RT for 1 h. Following five rounds of washes with PBS-1% Tween 20 plus one round of washing with distilled water, the bacterial samples were fixed with 2.5% glutaraldehyde and examined with an H7650 electron microscope (Hitachi Ltd., Tokyo, Japan) at an accelerating voltage of 80 kV.

**Construction of the ΔbgaC mutant of S. suis.** A spectinomycin resistance (Spc-) cassette was designed to disrupt into the bgaC gene of S. suis 2 strain 05ZYH33 via homologous recombination88. First, the Spc- cassette amplified from pSET22 was cloned into the pUC18 vector (Promega) to give the intermediate plasmid pUC18-Spc (Table 1), and then the two DNA fragments (LA and RA) flanking the bgaC gene were separately inserted into the pUC18-Spc vector, giving the knockout plasmid pUC::bgaC (Table 1). Second, the pUC::bgaC plasmid was electroporated into the competent cells of S. suis 05ZYH33 as we described before88 to acquire the transformants with Spectinomycin resistance. Finally, the multiplex-PCR technique combined with RT-PCR was utilized to screen confirm the candidate ΔbgaC mutant (Table 3), which was further verified by direct DNA sequencing analyses.

**Cell assays for bacterial adherence and phagocytosis.** The grown S. suis bacteria (WT & ΔbgaC) were processed as Hytonen and coworkers described89. The two
different cell lines used have included Hep-2 (human laryngeal epithelial cell line) and murine macrophage Raw 264.7 cells\(^2\). Hep-2 cell line is used to evaluate bacterial adherence whereas the Raw264.7 cells are tested to address its ability of anti-phagocytosis. Cell cultivation-based analyses were conducted as we recently reported\(^2\).

**Mice infections.** BALB/c (4-week old, female) mice were challenged with S. suis strains (WT \& ΔβgaC mutant) at a dose of 10\(^5\) CFU per mouse. THB was used as a negative control. Totally, three groups were involved, each of which included 10 mice. Clinical syndromes of the infected mice were monitored for two weeks. Of particular note, deaths were recorded and moribund animals were humanely killed. All experiments on live vertebrates in this study were approved by Ethics Committee of Research Institute for Medicine of Nanjing Command and performed in accordance with the relevant guidelines and regulations\(^3,4\).

**Bioinformatics, structural and statistical analyses.** The protein sequences of BgaC homologues of different organisms were derived from S. dysgalactiae, S. pneumoniae, and S. suis, respectively. The multiple alignments were conducted using ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/index.html), and the resultant output was processed by program ESPript 2.2 (http://espript.ibcp.fr/ESPript/ cgi-bin/ESPript.cgi)?\(^5\). The structure of S. suis BgaC homologue was modelled through CPHmodels 3.0 Server (http://www.cbs.dtu.dk/services/CPHmodels), and superimposed with the known structure of S. pneumoniae BgaC.

All assays were carried out in triplicate at least three times. Statistical analyses were performed using Student t test. Differences were considered statistically significant when the calculated P value was <0.05.

**Acknowledgments**

This work was supported by the start-up package of Zhejiang University (Youjun Feng), the National Natural Science Foundation of China (grants 31170124, 81371768, 81172794 and 31300119), National S&T Project for Infectious Diseases Control (grants 2012ZX10004-003, 2013ZX10004-203 and 2013ZX10004-218), Key Project of the Military

---

1. Feng, Y., Zhang, H., Ma, Y. & Gao, G. F. Uncovering newly emerging variants of Streptococcus suis. *Future Microbiol* 157, 2369–73 (2011).
2. Zhang, A. et al. Functional definition and global regulation of Zur, a zinc uptake regulon: identification and characterization of the suilysin gene and expression of MRP and EF correlates with high virulence of highly invasive Streptococcus suis serotype 2 strain 05ZYH33 through alteration of the bacterial cell metabolism. *Microbiology* 158, 1852–66 (2012).
3. Si, Y. et al. Contribution of glutamine synthetase to the virulence of Streptococcus suis serotype 2. *Vet Microbiol* 139, 80–8 (2009).
4. Li, Y. et al. Identification and proteome analysis of the two-component VirR/VirS system in epidemic Streptococcus suis serotype 2. *FEBS Microbiol Lett* 333, 168–10 (2012).
5. Li, J. et al. The two-component regulatory system GubH contributes to the virulence of Streptococcus suis 2. *Vet Microbiol* 148, 99–104 (2011).
6. Han, H. et al. The two-component system hilH/hilC contributes to the virulence of Streptococcus suis serotype 2 strain 05ZYH33 through alteration of the bacterial cell metabolism. *Microbiology* 158, 1852–66 (2012).
7. Willenborg, J. et al. Identification and characterization of the unsaturated fatty acid biosynthesis to its cognate promoters. *FEMS Microbiol Lett* 288, 1120–13 (2012).
8. Feng, Y. & Cronan, J. E. A new member of the Fad regulon: FadH by FadR and ArcA. *J Bacteriol* 191, 6320–8 (2009).
9. Feng, Y. & Cronan, J. E. Overlapping repressor binding sites result in additive regulation of *Escherichia coli* FadD by FadR and ArcA. *J Bacteriol* 192, 4289–99 (2010).
10. Chen, C. et al. A glimpse of streptococcal toxic shock syndrome from comparative genomics of S. suis 2 Chinese isolates. *PLoS One* 2, e315 (2007).
11. Li, J. et al. Contribution of glutamine synthetase to the virulence of Streptococcus suis serotype 2 strain 05ZYH33 through alteration of the bacterial cell metabolism. *Microbiology* 158, 1852–66 (2012).
12. Si, Y. et al. Contribution of glutamine synthetase to the virulence of Streptococcus suis serotype 2. *Vet Microbiol* 139, 80–8 (2009).
13. Zhang, X. H. et al. Identification and characterization of unsine S-monomophosphate dehydrogenase in Streptococcus suis type 2. *Microbiol Path* 47, 267–73 (2009).
14. Cao, M. et al. Functional definition of LuxS, an autoinducer-2 (AI-2) synthase and its role in full virulence of Streptococcus suis serotype 2. *J Microbiol* 49, 1000–11 (2011).
15. Wang, Y., Zhang, W., Wu, Z., Zhu, X. & Lu, C. Functional analysis of LuxS in Streptococcus suis reveals a key role in biofilm formation and virulence. *Vet Microbiol* 152, 151–60 (2011).
16. Mandanici, F. et al. Surface protein of Streptococcus suis serotype 2 identified by proteomics protects mice against infection. *J Proteomics* 73, 2369–73 (2011).
17. Li, Y. et al. Identification of a surface protein of Streptococcus suis and evaluation of its immunogenic and protective capacity in pigs. *Infect Immun* 74, 305–12 (2006).
18. Feng, Y. et al. Existence and characterization of allelic variants of Sao, a newly identified surface protein from *Streptococcus suis*. *FEBS Microbiol Lett* 278, 80–8 (2007).
19. Li, Y. et al. Immunization with recombinant Sao protein confers protection against Streptococcus suis infection. *Clin Vaccine Immunol* 14, 937–43 (2007).
20. Yuan, Z. Z. et al. Molecular mechanism by which surface antigen HP0197 mediates host cell attachment in the pathogenic bacteria *Streptococcus suis*. *J Biol Chem* 288, 956–63 (2013).
21. Zhang, A. et al. Identification of a surface protective antigen, HP0197 of *Streptococcus suis* serotype 2. *Vaccine* 27, 5209–13 (2009).
22. Jeong, J. K. et al. Characterization of the *Streptococcus pneumoniae* BgaC protein as a novel surface β-galactosidase with specific hydrolysis activity for the BgaC-dependent activation of biotin metabolism. *J Bacteriol* 191, 3011–23 (2009).
23. Dalia, A. B., Standish, A. J. & Weiser, J. N. Three surface exoglycosidases from *Streptococcus pneumoniae*, NanA, BgaA, and StH, promote resistance to opsonophagocytic killing by human neutrophils. *Infect Immun* 78, 2108–16 (2010).
24. Limoli, D. H., Sladek, J. A., Fuller, I. A., Singh, A. K. & King, S. J. BgaA acts as an adhesin to mediate attachment of some pneumococcal strains to human epithelial cells. *Microbiology* 157, 2369–81 (2011).
25. Cheng, W. et al. Structural insights into the substrate specificity of *Streptococcus pneumoniae* beta(1,3)-galactosidase BgaC. *J Biol Chem* 287, 22910–8 (2012).
26. Feng, Y. & Cronan, J. E. Complex binding of the FabR repressor of bacterial unsaturated fatty acid biosynthesis to its cognate promoters. *Mol Microbiol* 80, 195–218 (2011).
27. Feng, Y. et al. A Francisella virulence factor catalyses an essential reaction of biotin synthesis. *Mol Microbiol* 91, 300–14 (2014).
28. Takamatsu, D., Osaki, M. & Sekizaki, T. Construction and characterization of *Streptococcus suis-Escherichia coli* shuttle cloning vectors. *Plasmid* 45, 101–13 (2001).
29. Hyönten, J., Haataja, S. & Finne, J. Use of flow cytometry for the adhesion analysis of *Streptococcus pyogenes* mutant strains to epithelial cells: investigation of the possible role of surface iaspilinase and cysteine protease, and the transcriptional regulator Rgg. *BMC microbiology* 6, 18 (2006).
30. Feng, Y., Xu, J., Zhang, H., Chen, Z. & Srinivas, S. *Brucella* BioR regulator defines a complex regulatory mechanism for bacterial biotin metabolism. *J Bacteriol* 195, 3451–67 (2013).
31. Feng, Y. & Cronan, J. E. A new member of the *Escherichia coli* fab regulon: transcriptional regulation of fabM (sbaW). *J Bacteriol* 191, 6320–8 (2009).
32. Feng, Y. & Cronan, J. E. Overlapping repressor binding sites result in additive regulation of *Escherichia coli* FadD by FadR and ArcA. *J Bacteriol* 192, 4289–99 (2010).
33. Chen, C. et al. A glimpse of streptococcal toxic shock syndrome from comparative genomics of S. suis 2 Chinese isolates. *PLoS One* 2, e315 (2007).
Twelfth Five-Year Research Program of PLA (grants AWS11C001 and AWS11C009), Key Technology R&D Program of Jiangsu Province, China (grants BE2012609 and BE2013603). Dr. Feng is the recipient of "Young 1000 Talents" Award.

**Author contributions**

Y.F., C.W., D.H. and F.Z. conceived and designed this project and experiments. D.H., F.Z., Y.F., H.Z., L.H., X.G., M.G., M.C. and F.Z. performed the experiments and contributed to the development of the figures and tables. Y.F., D.H., C.W., H.Z., J.Z., X.P. and J.T. analyzed the data. Y.F., C.W., H.Z. and D.H. wrote this manuscript.

**Additional information**

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Hu, D. et al. The β-galactosidase (BgaC) of the zoonotic pathogen *Streptococcus suis* is a surface protein without the involvement of bacterial virulence. *Sci. Rep.*, 4, 4140; DOI:10.1038/srep04140 (2014).